Quarterly ResultMay 11, 2026, 04:03 PM
Aktis Oncology Advances AKY-2519 & AKY-1189 Trials; Q1 Net Loss $18.3M
AI Summary
Aktis Oncology reported its first quarter 2026 financial results and provided significant business updates. The company initiated a Phase 1b clinical trial for AKY-2519 in metastatic castration-resistant prostate cancer, with preliminary data expected in 2027, and plans a second Phase 1b basket trial for AKY-2519 in H2 2026. Additionally, AKY-1189 received FDA Fast Track designation for metastatic urothelial cancer, with preliminary Phase 1b data anticipated in Q1 2027. For Q1 2026, Aktis reported a net loss of $18.3 million, an increase from $15.0 million in the prior year, while collaboration revenue grew to $3.2 million. The company maintains a strong cash position of $538.5 million, expected to fund operations into 2029.
Key Highlights
- Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer.
- Preliminary data from AKY-2519 mCRPC trial anticipated in 2027.
- AKY-2519 clinical imaging and dosimetry data to be presented at 2026 ASCO Annual Meeting.
- Received FDA Fast Track designation for AKY-1189 for metastatic urothelial cancer.
- Preliminary data from AKY-1189 Phase 1b trial expected in Q1 2027.
- Q1 2026 net loss was $18.3 million, compared to $15.0 million in Q1 2025.
- Q1 2026 collaboration revenue increased to $3.2 million from $1.4 million YoY.
- Cash, cash equivalents, and marketable securities totaled $538.5 million as of March 31, 2026.